Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assurance

Barnes, Diana M.; Millis, Rosemary R.; Beex, L.V.A.M.; Thorpe, Susan M.; Leake, Robin

doi:10.1016/s0959-8049(98)00149-x

Cited by 72 publications

(51 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to previous studies [8] no external gold standard is necessary to derive a cutoff by this method. Nevertheless, the derived cutoffs for ER, PgR and HER2 showed high concordance with results from biochemical methods despite, e.g., widespread concerns of the inaccuracy of immunohistochemistry [49,50]. The comparability of array normalized data from 25 different datasets was good leading to similar cutoffs.…”

Section: Discussionmentioning

confidence: 68%

Data driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer

Karn

Metzler

Ruckhäberle

et al. 2009

Breast Cancer Res Treat

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 68%

Data driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer

Karn

Metzler

Ruckhäberle

et al. 2009

Breast Cancer Res Treat

View full text Add to dashboard Cite

“…Their study population differs from ours in several respects. Their criterion for ER positivity was set at the lower level of > 3 fmol mg Ð1 cytosol; in practice, at our and other institutions, the clinical cut-off value for ER-positivity in the ligand binding assay was usually > 10 fmol mg Ð1 (Barnes et al, 1998). All patients in the study of Elledge et al received tamoxifen as initial therapy for metastatic disease.…”

Section: Discussionmentioning

confidence: 98%

Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer

et al. 1999

View full text Add to dashboard Cite

The present study investigated the interaction between c-erbB2 overexpression and the response to first-line endocrine therapy in patients with advanced breast cancer. The primary tumours of 241 patients who were treated at first relapse with endocrine therapy were assessed for overexpression of c-erbB2 by immunohistochemistry. c-erbB2 was overexpressed in 76 (32%) of primary breast cancers and did not correlate with any other prognostic factor. The overall response to treatment and time to progression were significantly lower in patients with c-erbB2-positive tumours compared to those that were c-erbB2-negative (38% vs 56%, P = 0.02; and 4.1 months vs 8.7 months, P < 0.001, respectively). In multivariate analysis, c-erbB2 status was the most significant predictive factor for a short time to progression ( P = 0.0009). In patients with ER-positive primary tumours treated at relapse with tamoxifen ( n = 170), overexpression of c-erbB2 was associated with a significantly shorter time to progression (5.5 months vs 11.2 months, P < 0.001). In conclusion, overexpression of c-erbB2 in the primary tumour is an independent marker of relative resistance to first-line endocrine therapy in patients with advanced breast cancer. In patients with ER-positive primary tumours, the overexpression of c-erbB2 defines a subgroup less likely to respond to endocrine therapy. © 1999 Cancer Research Campaign

show abstract

“…23 Although it is accepted that hormone receptornegative patients should not be considered for endocrine therapy, many studies show that a proportion of these patients do respond to such treatment. 24 Similarly, it is recommended that only patients with HER2-amplified tumors should be considered for target therapy with Trastuzumab. However, some recent studies have shown that a proportion of HER2-negative patients could benefit from this therapy as well.…”

Section: Discussionmentioning

confidence: 99%

“…Consistent and accurate estrogen and progesterone receptors results are important because they are an integral part of therapeutic decision making. [1][2][3] The decision to treat some women with endocrine therapy for up to 10 years is dependent on the results of these tests. The 'Ad hoc' consensus committee has implemented detailed recommendations on estrogen receptor testing by immunohistochemistry.…”

mentioning

confidence: 99%

Delay to formalin fixation effect on breast biomarkers

et al. 2009

View full text Add to dashboard Cite

Delay to formalin fixation may invalidate hormone receptors and HER2 analyses. Invalid results of tumor markers could significantly alter the type of adjuvant therapy a patient receives and potentially impact outcome. The purpose of this study was to determine the effects of progressive delay to formalin fixation on breast cancer biomarkers. Ten palpable invasive breast cancers were resected and underwent immediate gross evaluation. For each case, the procured tumor was divided into eight parts and consecutively fixed after 0, 10, 30 min, 1, 2, 4, and 8 h; one section was kept in saline and stored overnight at 41C. Two tissue microarray blocks were constructed. Estrogen and progesterone receptors and HER2 immunohistochemistry and fluorescence in situ hybridization were carried out. Statistical analyses including non-parametric sign test, exact McNemar's test and Page's L test were used. All 10 cases were invasive ductal carcinomas. Q score X6 was identified in five cases for estrogen receptor and four for progesterone receptor. Mean Q score started to decline at the 2 h mark for estrogen receptor and 1 h mark for progesterone receptor. Lowest score was at 8 h mark for estrogen receptor and overnight for progesterone receptor. HER2 fluorescence in situ hybridization started to be compromised for interpretation at the 1 h mark and became statistically significant at the 2 h mark (Po0.03). To avoid delay to formalin fixation as a factor negatively affecting on breast biomarkers, we recommend not to delay formalin fixation for more than 1 h and not to store specimens overnight.

show abstract

Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assurance

Cited by 72 publications

References 20 publications

Data driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer

Data driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer

Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer

Delay to formalin fixation effect on breast biomarkers

Contact Info

Product

Resources

About